Meningeal carcinomatosis from breast cancer

Spinal cord vs. brain involvement

Gerald Clamon, Bradley Doebbeling

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Twenty-two patients with meningeal carcinoma due to breast cancer were restrospectively evaluated to determine what prognostic factors affected survival. Five patients survived for more than one year. The therapy in these long-term survivors was similar to that of those suffering early death. Patients with primarily brain symptoms survived a median of 21 days vs. 150 days in those with primarily spinal cord symptoms (p = 0.026). The site of involvement may be an important stratification parameter for future prospective trials.

Original languageEnglish (US)
Pages (from-to)213-217
Number of pages5
JournalBreast Cancer Research and Treatment
Volume9
Issue number3
DOIs
StatePublished - Oct 1987
Externally publishedYes

Fingerprint

Meningeal Carcinomatosis
Spinal Cord
Breast Neoplasms
Brain
Survivors
Carcinoma
Survival
Therapeutics

Keywords

  • breast cancer
  • meningeal
  • metastasis
  • site

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Meningeal carcinomatosis from breast cancer : Spinal cord vs. brain involvement. / Clamon, Gerald; Doebbeling, Bradley.

In: Breast Cancer Research and Treatment, Vol. 9, No. 3, 10.1987, p. 213-217.

Research output: Contribution to journalArticle

@article{bf18c943959e4c2a8d73a151a284e1a9,
title = "Meningeal carcinomatosis from breast cancer: Spinal cord vs. brain involvement",
abstract = "Twenty-two patients with meningeal carcinoma due to breast cancer were restrospectively evaluated to determine what prognostic factors affected survival. Five patients survived for more than one year. The therapy in these long-term survivors was similar to that of those suffering early death. Patients with primarily brain symptoms survived a median of 21 days vs. 150 days in those with primarily spinal cord symptoms (p = 0.026). The site of involvement may be an important stratification parameter for future prospective trials.",
keywords = "breast cancer, meningeal, metastasis, site",
author = "Gerald Clamon and Bradley Doebbeling",
year = "1987",
month = "10",
doi = "10.1007/BF01806382",
language = "English (US)",
volume = "9",
pages = "213--217",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "3",

}

TY - JOUR

T1 - Meningeal carcinomatosis from breast cancer

T2 - Spinal cord vs. brain involvement

AU - Clamon, Gerald

AU - Doebbeling, Bradley

PY - 1987/10

Y1 - 1987/10

N2 - Twenty-two patients with meningeal carcinoma due to breast cancer were restrospectively evaluated to determine what prognostic factors affected survival. Five patients survived for more than one year. The therapy in these long-term survivors was similar to that of those suffering early death. Patients with primarily brain symptoms survived a median of 21 days vs. 150 days in those with primarily spinal cord symptoms (p = 0.026). The site of involvement may be an important stratification parameter for future prospective trials.

AB - Twenty-two patients with meningeal carcinoma due to breast cancer were restrospectively evaluated to determine what prognostic factors affected survival. Five patients survived for more than one year. The therapy in these long-term survivors was similar to that of those suffering early death. Patients with primarily brain symptoms survived a median of 21 days vs. 150 days in those with primarily spinal cord symptoms (p = 0.026). The site of involvement may be an important stratification parameter for future prospective trials.

KW - breast cancer

KW - meningeal

KW - metastasis

KW - site

UR - http://www.scopus.com/inward/record.url?scp=0023178948&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023178948&partnerID=8YFLogxK

U2 - 10.1007/BF01806382

DO - 10.1007/BF01806382

M3 - Article

VL - 9

SP - 213

EP - 217

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 3

ER -